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Establishment of human iPSC-based models for the
study and targeting of glioma initiating cells
Ignacio Sancho-Martinez1,*,w, Emmanuel Nivet1,*,w, Yun Xia1,*,w, Tomoaki Hishida1, Aitor Aguirre1,
Alejandro Ocampo1, Li Ma1,2, Robert Morey3, Marie N. Krause1, Andreas Zembrzycki4, Olaf Ansorge5,
Eric Vazquez-Ferrer1, Ilir Dubova1,2, Pradeep Reddy1, David Lam1, Yuriko Hishida1, Min-Zu Wu1,
Concepcion Rodriguez Esteban1, Dennis O’Leary4, Geoffrey M. Wahl6, Inder M. Verma7, Louise C. Laurent3
& Juan Carlos Izpisua Belmonte1
Glioma tumour-initiating cells (GTICs) can originate upon the transformation of neural
progenitor cells (NPCs). Studies on GTICs have focused on primary tumours from which
GTICs could be isolated and the use of human embryonic material. Recently, the somatic
genomic landscape of human gliomas has been reported. RTK (receptor tyrosine kinase) and
p53 signalling were found dysregulated inB90% and 86% of all primary tumours analysed,
respectively. Here we report on the use of human-induced pluripotent stem cells (hiPSCs)
for modelling gliomagenesis. Dysregulation of RTK and p53 signalling in hiPSC-derived
NPCs (iNPCs) recapitulates GTIC properties in vitro. In vivo transplantation of transformed
iNPCs leads to highly aggressive tumours containing undifferentiated stem cells and their
differentiated derivatives. Metabolic modulation compromises GTIC viability. Last, screening
of 101 anti-cancer compounds identiﬁes three molecules speciﬁcally targeting transformed
iNPCs and primary GTICs. Together, our results highlight the potential of hiPSCs for studying
human tumourigenesis.
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A
dult gliomas are the most malignant human brain
tumours1, with no curative therapy available. Gliomas
can originate as a result of adult NPCs transformation to
glioma tumour-initiating cells (GTICs)1,2. However, strategies
for studying the mechanisms underlying the transformation of
adult human NPCs to GTICs remain scarce with most
mechanistic studies relying on the use of transgenic murine
models1. Recent reports have highlighted the potential of
reprogramming to induce the conversion of differentiated
glioma cells to a GTIC-like phenotype3. Despite much success,
reprogramming of cancer cells to GTICs requires the use of
already transformed cells isolated from a pre-existent
tumour1,3–10. Thus, and similar to the use of primary glioma
cells, such reprogrammed GTICs prevent functional studies on
the mechanisms leading to NPC transformation and tumour
initiation. Accordingly, functional studies on NPC transformation
and GTIC formation remain largely limited to the use of
differentiated neural derivatives11,12 and/or the use of murine
models1,13,14. Contrary to murine models, isolation of adult
human NPCs remains restricted to brain tissue material obtained
from patients with pathological conditions, such as epilepsy, or
post-mortem. As an alternative to study human gliomagenesis,
the use of primary fetal NPCs and NPCs differentiated from
human embryonic stem cells has been reported1,2,10,15,16.
However, the use of embryonic/fetal material remains the
subject of ethical controversy and limits the possibility for
investigating the role of different mutations in various genetic
backgrounds represented in the human population.
In 2006, Kazutoshi Takahashi and Shinya Yamanaka were able
to reprogram somatic cells into pluripotent stem cells upon the
forced expression of a small number of deﬁned genes17.
Reprogramming to human-induced pluripotent stem cells
(hiPSCs) possesses the inherent advantages of voiding the need
for embryonic material while allowing for the generation of
pluripotent cells from any given genetic background in a
patient-speciﬁc manner. The possibility for generating patient-
speciﬁc iPSCs holds great promise for the future development of
autologous cell therapies as well as open unprecedented
opportunities for disease modelling and drug discovery
studies18. In addition, modelling of complex phenotypes,
such as aging, can be accomplished by overexpressing
speciﬁc mutant genes in otherwise wild-type hiPSCs19,20.
Therefore, the use of hiPSCs, and/or their derivatives, in which
deﬁned genetic alterations related to cancer are introduced might
represent a suitable strategy for the establishment of human
cancer models.
Here we report on the establishment of tractable in vitro and
in vivo hiPSC models for the study of human iNPC trans-
formation to GTIC-like cells. Genetic manipulation of p53 and
receptor tyrosine kinase signalling leads to the acquisition
of cancer stem cell-like features in vitro, including enhanced
self-renewal and migratory properties alongside metabolic
reprogramming. Transformation of iNPCs to GTIC-like
cells leads to the generation of human glioma-like tumours
with distinct histopathological features upon orthotopic
transplantation of 500 cells into the murine brain as well as in
serial transplantation experiments. Ultimately, our results
highlight the suitability of human iPSC technologies for the
modelling of human cancer.
Results
Transformation of human iPSC-derived neural progenitors.
Mutations affecting components of the p53 signalling pathway
are collectively observed in B86% of all human gliomas21.
Therefore, we ﬁrst generated hiPSC lines from healthy/‘wild-type’
human ﬁbroblasts (hereafter referred to as WTiPSCs) and lines in
where p53 was knocked down (hereafter referred to as
p53KDiPSCs) (Supplementary Fig. 1a). All hiPSCs presented
the typical hallmarks of pluripotency including in vivo teratoma
formation in the absence of apparent malignant transformation
(Supplementary Fig. 1b–f). Next, we differentiated NPCs from the
generated hiPSCs (Supplementary Fig. 2a). Immunoﬂuorescence
analysis as well as multilineage differentiation potential
conﬁrmed the NPC identity of the differentiated cells (hereafter
referred to as iNPCs) (Supplementary Fig. 2b–d). We have
previously reported that human glioma inﬁltration is driven by
activation of Src-family kinases (SFKs) and targeting SFKs
has emerged as an attractive therapeutic approach currently
under development22–25. In addition, Brennan et al.21 described
mutations collectively leading to PI3K and MAPK
hyperactivation in B90% of human gliomas. Therefore, we
additionally generated iNPCs-overexpressing mutant-active
versions of Src (to mimic inﬁltrative behaviour), EGFR
(duplicated and/or mutated in B57% of human gliomas)21 and
Ras (mutated in B1% of human gliomas and a common
upstream regulator of both PI3K and MAPK signalling)21.
Lentivirus-mediated overexpression of the different mutant
genes in either 293T cells or WT- and p53KD- iNPCs (namely Ras/
EGFR/SrciNPCs and p53KD-Ras/EGFR/SrciNPCs, respectively)
conﬁrmed the hyperactivation of PI3K and MAPK pathways as
demonstrated by increased AKT and ERK phosphorylation,
respectively (Supplementary Fig. 2a,e,f).
GTICs were ﬁrst isolated based on the expression of CD133
and thus CD133þ thought to unequivocally label glioma cells
with stem cell properties26. However, CD133 glioma cells
presenting stem cell and GTIC properties have also been
reported27,28 and CD133þ cells found in a variety of normal
tissues other than tumours29. Nevertheless, we sought to
investigate the role of putative GTIC surface markers for
enriching cancer populations with stem cells properties. On the
basis of our ﬂow cytometry results (Fig. 1a), we ﬁrst separated
CD133þ and CD133 cells and performed in vitro single-cell
tumour forming assays. To avoid limiting our analyses to a
single marker, we also sorted out CD15þ and CD15 cells as
well as CXCR4þ and CXCR4 populations. All different cell
populations demonstrated comparable colony forming potential
(Supplementary Fig. 2g). These results are in agreement with the
notion that GTICs are very heterogeneous. Indeed, a universally
accepted panel of markers for the characterization and isolation
Figure 1 | Transformation of human iNPCs results in the acquisition of a GTIC-like phenotype in vitro. (a) Flow cytometry analysis for the indicated
markers in different transformed and wild-type iNPC groups (n¼4/group with technical duplicates). (b) Transformation of human iNPCs leads to
increased self-renewal properties only in cells where PI3K and MAPK signalling is dysregulated by overexpression of Ras/EGFR/Src mutant genes as
highlighted by single-cell self-renewal assays (n¼ 3/group with 24 technical replicates). (c) iNPC transformation results in the upregulation of endogenous
NANOG as highlighted by western blot analyses. (d) NANOG expression is upregulated in primary human adult glioma samples. (e) Unsupervised cluster
analysis of mRNA expression data highlighting the similarities between transformed iNPCs and primary GTICs. Please note that p53KDiNPCs are more
similar to WTiNPCs than to primary GTICs. (f,g) Transformation of human iNPCs induces glycolytic (f) and oxidative phosphorylation changes as indicated
by Seahorse analysis (g), as measured by ECAR and OCR (n¼4/group with four technical replicates). Data are represented as mean±s.d. P values were
calculated by Student’s t-test or Mann–Whitney test when appropriate and represented as follows: *Po0.05. Scale bars, 200mm (d).
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of GTICs is yet to be reported30. Variability in surface marker
expression in cancer cells bearing stem cell properties is not
exclusive to gliomas and has now been observed in a variety of
human tumours1,3–7,9,10. Because of surface marker heterogeneity
and their expression in certain non-transformed adult stem
cells, recent reports advocate for the characterization of cancer
stem cells based on functional properties, such as multilineage
differentiation potential and tumour formation upon serial
transplantation1,3–7,9,10. Accordingly, we next decided to
investigate the self-renewal potential of non-sorted iNPCs by
performing single-cell assays. Enhanced self-renewal properties
were observed in all iNPCs where PI3K/MAPK signalling was
dysregulated (Fig. 1b). Furthermore, NANOG, a protein
expressed in iPSCs, was found upregulated in transformed
iNPCs (Fig. 1c). Interestingly, immunohistochemical analyses of
human brain tumour samples further conﬁrmed NANOG
expression in grade IV gliomas (Fig. 1d). Lack of TRA1-60 and
TRA1-81 expression (Fig. 1a) further demonstrated that NANOG
expression was due to transformation and not the presence of
undifferentiated hiPSCs.
Transformation of human NPCs generates GTIC-like cells. We
next compared the generated iNPCs with primary GTICs,
isolated and characterized by Pollard et al.5, by performing
genome-wide analyses. Genome-wide expression data
demonstrated that transformed iNPCs closely resemble primary
GTICs at the molecular level, though some differences were
readily observed among the different groups. WTiNPCs were most
similar to p53KDiNPCs, while Ras/EGFR/SrciNPCs and p53KD-Ras/EGFR/
SrciNPCs were very similar to each other and intermediate
between the WTiNPC/p53KDiNPC cluster and primary GTICs
(Supplementary Data 1, analysis of the variance (ANOVA)
q value o0.01 and variance ﬁlter¼ 0.2 using Qlucore).
The corresponding heatmap showed ﬁve large clusters of genes
that were differentially expressed among WTiNPCs, p53KDiNPCs,
Ras/EGFR/SrciNPCs, p53KD-Ras/EGFR/SrciNPCs and GTICs (Fig. 1e,
clusters I–V and Supplementary Data 2). Importantly, genes
in cluster V showed higher expression in the GTICs,
Ras/EGFR/SrciNPCs and p53KD-Ras/EGFR/SrciNPCs compared with
ESCs, WTiNPCs, and p53KDiNPCs (Fig. 1e, cluster V and
Supplementary Data 2). Of the ﬁve clusters, cluster V showed
the highest number of signiﬁcant enrichments on pathways
analysis, and was enriched for several cell growth-, proliferation-
and cancer-associated pathways. Notably, DNA methylation
analysis conﬁrmed a more undifferentiated phenotype for
Ras/EGFR/SrciNPCs and p53KD-Ras/EGFR/SrciNPCs (Supplementary
Table 1).
Changes in the energetic metabolism are generally observed in
cancer cells, the so-called Warburg effect31. In agreement,
Seahorse analyses demonstrated the clear metabolic
reprogramming of transformed iNPCs (Fig. 1f,g). RNA
expression analyses highlighted the upregulation of glycolytic
genes typically associated with metabolic alterations in GTICs in
the transformed iNPCs, including: PKM2; HK; GLUT3
(a gene recently described as critical for glucose uptake in
GTICs)6; and LDHB (a gene commonly upregulated in gliomas
bearing IDH mutations)32 (Supplementary Fig. 3a). Higher
lactate production and lower glucose consumption in
transformed iNPCs revealed signiﬁcant differences in the
lactate/glucose ratio (Supplementary Fig. 3b). Non-labelled mass
spectrometry highlighted, as before, higher similarities between
p53KD- and WTiNPCs, an intermediate proﬁle in Ras/EGFR/SrciNPCs
and marked differences in the levels of metabolites involved in
carbon and aminoacid metabolism in p53KD-Ras/EGFR/SrciNPCs
(Supplementary Fig. 3c). Next, U-13C glucose labelling was
used to monitor carbon ﬂux in the transformed iNPCs as
compared with WTiNPCs. No signiﬁcant differences in levels of
production of glycolytic metabolites were found among the four
lines, except for increased glucose ﬂux into lactate and glycine in
p53KD-Ras/EGFR/SrciNPCs, (Supplementary Fig. 3d). Interestingly,
we observed much lower inﬂux of glucose into glutamate
production and into the trichloroacetic acid or tricarboxylic
acid cycle (as highlighted by differential labelling of aspartate,
malate, fumarate and a-ketoglutarate) in Ras/EGFR/SrciNPCs and
p53KD-Ras/EGFR/SrciNPCs, compared with WT- and p53KDiNPCs,
which shared a similar metabolic proﬁle (Supplementary Fig. 3d).
Quantiﬁcation of ROS levels further highlighted metabolic
reprogramming and demonstrated reduced mitochondrial ROS
formation upon iNPC transformation, whereas total ROS levels
remained comparable across all different groups (Supplementary
Fig. 4a,b). MitoTracker analysis indicated that disruption of
signalling pathways resulted in morphological mitochondrial
changes and higher fragmentation of mitochondrial networks as
compared with WTiNPCs (Supplementary Fig. 4c).
To test whether transformation of iNPCs resulted in the
functional acquisition of GTIC-like properties in vivo4,7,9, we
performed xenograft transplantation studies. Orthotopic injection
of transformed iNPCs (500,000 cells) into the murine brain
resulted in the rapid appearance of highly aggressive tumours
(Fig. 2a and Supplementary Table 2). Tumours were then
analysed for the presence of classical hallmarks of human
glioblastoma multiforme (GBM) such as pleomorphic GFAPþ
glial cells, mitoses, diffuse inﬁltrative growth, pseudopalisading
microscopic necrosis and microvascular proliferation (Fig. 2b–d
and Supplementary Fig. 5a,b). Immunoﬂuorescence analysis
demonstrated the presence of de-differentiated NESTINþ and
SOX2þ cancer cell populations as well as oligodendrocytes (O4),
astrocytes (GFAP) and neurons (TUJ-1) conﬁrming the in vivo
differentiation potential of the generated GTIC-like cells (Fig. 2c
and Supplementary Fig. 5b). In addition to the presence of
undifferentiated tumour cells, all tumours presented mitotic
ﬁgures. Thus, these data suggested a pathological classiﬁcation as
high-grade astrocytomas (grades III–IV). In line with the
differences observed in vitro, in vivo analyses highlighted
intergroup differences reﬂecting different glioma subtypes.
Figure 2 | Transformation of human iNPCs results in the acquisition of GTIC-like properties in vivo. (a) Representative pictures demonstrating the
formation of vascularized tumours only in animals receiving transformed, and not wild-type, human iNPCs. (b) Haematoxylin-eosin staining demonstrating
the presence of highly aggressive brain tumours upon orthotopic transplantation of transformed human iNPCs into the murine brain. (c) Immuno-
ﬂuorescence analysis demonstrating the presence of undifferentiated SOX2þ cells (red) as well as differentiation into the three major neural lineages upon
transplantation of transformed human iNPCs. Please note the higher cellularity in tumours derived upon transplantation of p53KD-Ras/EGFR/SrciNPCs. HUNU
(green) indicates human nuclear antigen staining; O4 (green) indicates oligodendrocyte differentiation; Tuj1 (red) indicates neuronal differentiation;
and GFAP (red) indicates glial differentiation. pERK (purple) and pAKT (purple) were only detected in tumours generated upon transplantation of
iNPCs-overexpressing mutant versions of Ras/EGFR/Src. Cells were counterstained with DAPI (blue) and their proliferative state monitored by Ki67
immunostaining (red). (d) Brain tumours derived from human p53KD-Ras/EGFR/SrciNPCs demonstrated the presence of human vessels derived from the
injected GTIC-like cells as indicated by CD31 and HUNU co-localization. n¼ 5 animals/condition. A minimum of three brain sections/animal/condition
were analysed. Scale bars, 200mm (b); 100mm or 25mm as indicated (c); and 25mm (d).
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Tumours arising from p53KDiNPCs were reminiscent of
‘small-cell’ GBM, showing elongated spindle cells with
eosinophilic cytoplasm alternating with clusters of compact cells
with little cytoplasm and a high nuclear:cytoplasmic ratio. These
tumours displayed a diffuse growth pattern but lacked the
pleomorphism usually seen in GBM and no obvious transition
zone to normal brain was detected. Brain tumours developed
upon injection of Ras/EGFR/SrciNPCs showed a nodular growth
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with perivascular spread but not much diffuse parenchymal
invasion was observed. Interestingly, some necrosis was
observed but no pseudopalisading. Notably, the pale cytoplasm
and elongated shape that were observed are reminiscent of
mesenchymal morphology. Lastly, from all three groups analysed,
the tumours developed after injection of p53KD-Ras/EGFR/SrciNPCs
closely resembled grade IV glioblastomas. These tumours
demonstrated the highest cellularity and massive necrotic areas
as well as microvascularization, pseudopalisading, breaching of
the pial surface and invasion of the subarachnoid space as seen in
GBM and gliosarcomas. Most notably, transdifferentiated human
CD31þ endothelial cells a feature of human gliomas for
promoting tumour vascularization33, were only observed upon
injection of p53KD-Ras/EGFR/SrciNPCs (Fig. 2d). Animals injected
with WTiNPCs lived their normal lifespan and did not present
brain tumours (Supplementary Table 2) whereas injection of
undifferentiated iPSCs led to the formation of well-deﬁned
embryonic-like teratomas histologically distinct from the brain
tumours generated upon transplantation of transformed iNPCs
(Supplementary Fig. 1e). Next, we performed xenograft
transplantation experiments with limited cell numbers as well
as secondary tumour formation assays. Among the transformed
groups, only iNPCs dysregulated for PI3K and MAPK signalling
(Ras/EGFR/SrciNPCs and p53KD-Ras/EGFR/SrciNPCs) were able to form
primary tumours when 500 cells were orthotopically injected into
the murine brain (Supplementary Fig. 6a and Supplementary
Table 3). Furthermore, serial transplantation of Ras/EGFR/SrciNPCs
and p53KD-Ras/EGFR/SrciNPCs resulted in the formation of highly
aggressive and inﬁltrative secondary tumours, presenting similar
histological characteristics to those observed in the respective
primary tumours, even upon secondary transplantation of 500
cells (Supplementary Fig. 6b–e and Supplementary Table 3). In
agreement with the similarities between p53KDiNPCs and
WTiNPCs, p53KDiNPCs did not lead to secondary tumour
formation upon serial transplantation regardless of the number
of cells injected (Supplementary Table 3).
Transformation of iNPCs results in differential SOX2 binding.
To highlight potential differences between normal iNPCs and
GTICs, we analysed the binding of SOX2, a transcription factor
common to both WTiNPCs and GTICs. ChIP-seq experiments
demonstrated differential binding of SOX2 in primary GTICs and
transformed GTIC-like cells as compared with WTiNPCs (Fig. 3a).
Correlation analysis between ChIP and mRNA expression data
highlighted a total of approximately eight genes commonly regu-
lated by SOX2 that were both differentially bound as well as dif-
ferentially expressed between primary GTICs/p53KD-Ras/EGFR/
SrciNPCs as compared with WTiNPCs (Supplementary Data 3,
highlighted in red). In agreement with a more undifferentiated
phenotype, SOX2 preferentially bound to gene promoters asso-
ciated to cell dedifferentiation and neural development processes in
p53KD-Ras/EGFR/SrciNPCs. Interestingly, one gene, COX6A1, a gene
blocking Bax-induced apoptosis, showed decreased SOX2 binding
associated with increased expression in the GTICs and p53KD-Ras/
EGFR/SrciNPCs compared with the WTiNPCs and p53KDiNPCs
(Fig. 3a). Genes for which decreased SOX2 binding was associated
with decreased expression in GTICs and p53KD-Ras/EGFR/SrciNPCs
compared with WTiNPCs and p53KDiNPCs were MAP2K5/ERK5,
whose activities have been associated with tumour development
and the acquisition of mesenchymal stem-like properties in cancer
cells34, and C10orf67, a susceptibility locus associated with
sarcoidosis and Crohn’s disease (Fig. 3a).
Chemical screening highlights compounds targeting GTICs.
We next tested the suitability of the generated platforms for the
testing of chemicals with potential anti-cancer activities. First we
investigated the GTIC dependence for hyperactive PI3K/MAPK
signalling and their causative role in the acquisition of stem cell
properties and metabolic reprogramming. Notably, only MAPK
inhibition with PD098059 restored normal glycolytic activities,
whereas inhibition of both, PI3K (LY294002) and MAPK
signalling, reduced oxidative phosphorylation to the levels
observed in WTiNPCs (Fig. 3b,c). In addition, chemical
inhibition of PI3K and MAPK compromised stem cell self-renewal
properties (Supplementary Fig. 7). Next, we focused on
metabolic modulation by using: (i) Carbonyl cyanide
4-(triﬂuoromethoxy)phenylhydrazone (FCCP), a compound
dissipating mitochondrial membrane potential; (ii) rotenone in
conjunction with antimycin A (Rot/AA), both compounds
targeting complexes I and III and leading to the massive
production of ROS; and (iii) 2-DG, an analogue glucose acting as a
suicide inhibitor. Among all metabolic modulators, inhibition of
glycolysis by 2-DG, a compound previously reported for the
targeting of gliomas and currently in clinical testing, signiﬁcantly
compromised the self-renewal properties of transformed iNPCs
(Fig. 3d). Then, we performed MTS assays to assess cell viability in
the presence of metabolic chemical modulators. Interestingly,
FCCP did not show any consistent effect across the different
groups whereas the use of Rot/AA affected cell viability in all
iNPCs (Fig. 3e and Supplementary Fig. 8a). Importantly, inhibition
of glycolysis demonstrated a dramatic effect across the different
groups of transformed iNPCs, whereas WTiNPCs remained largely
unaffected (Fig. 3e). In view of these results, we next decided to
perform a proof-of-concept screening with 101 FDA-approved
anti-cancer compounds (Supplementary Fig. 8b and
Supplementary Table 4). MTS assays highlighted 16 different
compounds compromising cell viability (Supplementary Fig. 8c
and Supplementary Table 4, highlighted in red). Among the dif-
ferent compounds, nelarabine, letrozole and capecitabine, currently
under testing for the treatment of gliomas, demonstrated speciﬁcity
against transformed iNPCs and primary GTICs, whereas cabazi-
taxel also hampered WTiNPC viability (Fig. 4a).
Glioma cell inﬁltration remains a major cause of tumour
relapse and we have previously demonstrated that SFK signalling
mediates basal glioma invasion by activating MMP9 (ref. 25).
Two-chamber migration assays demonstrated enhanced
migratory properties in transformed iNPCs (Supplementary
Fig. 9a,b). RNA proﬁling demonstrated the signiﬁcant upregula-
tion of MMP9 in Ras/EGFR/SrciNPCs and p53KD-Ras/EGFR/SrciNPCs
(Supplementary Fig. 9c) and MMP9 inhibition signiﬁcantly
hampered migration (Supplementary Fig. 9b). In addition, all
identiﬁed anti-cancer compounds and two metabolic inhibitors
(2-DG and Rot/AA) hampered the migration of primary GTICs
and transformed iNPCs (Fig. 4b). Differentiation of cancer stem
cells is thought to give rise to less malignant populations that are
presumably more sensitive to chemotherapy, whereas the
self-renewing stem cell compartment is thought to contribute to
resistance and recurrence2,3,8,9,35–37. Self-renewal assays indicated
that Ras/EGFR/SrciNPCs and p53KD-Ras/EGFR/SrciNPCs possessed the
highest self-renewal potential, whereas p53KDiNPCs were more
similar to WTiNPCs (Supplementary Fig. 9d,e). Treatment with
the identiﬁed compounds signiﬁcantly compromised the
self-renewal properties of Ras/EGFR/SrciNPCs and p53KD-Ras/EGFR/
SrciNPCs (Fig. 4c). In addition, iNPC-differentiated neural cells
demonstrated higher susceptibility to chemical treatments
(Supplementary Fig. 10a). Next, we investigated the effect of the
identiﬁed compounds in established glioma lines. Treatment of
U-87 MG and LN229 glioma cells with the different compounds
demonstrated the efﬁcient induction of cell death with nelarabine
and letrozole, whereas capecitabine was largely ineffective
(Supplementary Fig. 10b). Last, we decided to test the effect of
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Figure 3 | Human iNPCs transformation leads to differential SOX2 binding and metabolic reprogramming. (a) Chromatin Immunoprecipitation with
SOX2 antibodies followed by deep-sequencing demonstrates differential binding of SOX2 in WTiNPCs as compared with transformed iNPCs and primary
GTICs. (b,c) Modulation of PI3K and MAPK signalling pathways with LY294002 (LY) and PD098059 (PD), respectively, reverts the metabolic changes
observed in transformed iNPCs as indicated by seahorse analysis. MAPK inhibition restores glycolytic activities (b), whereas inhibition of both, PI3K and
MAPK, reduced oxidative phosphorylation to the levels observed in WTiNPCs (c) (n¼4 group/condition with four technical replicates). (d) Inhibition of
glycolysis by 2-DG compromises self-renewal properties in transformed iNPCs (n¼4 group with four technical replicates). (e) Chemical induced glycolysis
inhibition (2-DG) and ROS production (Rot/AA) compromises transformed iNPC viability in MTS assays (n¼4 group/condition with four technical
replicates). Data are represented as mean±s.d. P values were calculated by Student’s t-test. *Po0.05.
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the identiﬁed compounds alongside metabolic modulators in a
more physiological setting. To this end, we relied on the
use of ex vivo organotypic brain slices5,6,38,39. Injection of
primary GTICs into 300mm brain slices resulted in the
formation of well-deﬁned tumour masses in less than 8 days
(Fig. 4d). Treatment of brain slices indicated a speciﬁc effect
against primary GTIC tumours with 2-DG, nelarabine and
letrozole, demonstrating the highest anti-tumour potential
(Fig. 4d,e).
Discussion
Cancer arises as a consequence of transforming ‘driver’ mutations
able to initiate tumour formation. Upon tumour initiation,
positive selection and clonal progression further leads to the
accumulation of ‘passenger’ mutations conferring additional
growth advantages. Identiﬁcation of driver mutations might
therefore allow not only for the establishment of targeted
therapies but also, most importantly, for the elucidation and
targeting of the early events underlying cancer formation.
Although enormous progress has been made, current
bioinformatics approaches tend to focus on diver mutations
found in high frequencies while underestimating the role that low
frequency mutations might play during carcinogenesis40–45.
Since their discovery, iPSCs have been widely used for the
modelling of genetic disorders and multiple reports have
highlighted the suitability of reprogramming as a platform for
drug discovery studies18,36. In an analogous manner, different
strategies have been used for the modelling of human
cancer2,3,10–15 including the generation of induced pluripotent
cancer cells by reprogramming of cancer cells to a pluripotent
state46,47 and the transformation of differentiated ﬁbroblast
by oncogenes and tumour suppressor genes to a cancer
stem cell-like phenotype37. More recently, conversion of
differentiated cancer cells to a multipotent cancer stem cell
phenotype upon overexpression of factors deﬁning GTIC
identity has been reported3. Reprogramming of differentiated
glioma cells to glioma stem cells opens the unprecedented
opportunity for investigating the dynamic dedifferentiation
processes leading to the appearance of GTICs (ref. 3). However,
the need for primary tumour material (or glioma cell lines) in
where transforming mutations are already present could prevent
studies on the role that speciﬁc mutations might play
during gliomagenesis. Directly addressing the lack of model for
studying driver mutations, the Tabar laboratory ﬁrst reported on
the use of NPCs differentiated from human ESCs for studying
the role that histone 3.3 mutations play in the formation of
pediatric gliomas2. Along a similar line, our own results
demonstrate the suitability of hiPSCs technologies for the
establishment of GTIC-like models recapitulating features
observed in adult human gliomas.
In summary, here we report on the application of iPSC
technologies for the establishment of tractable human GTIC-like
models in vitro and in vivo. Similar to conventional
disease modelling strategies based on the use of hiPSCs, the
establishment of hiPSC cancer models might facilitate the future
development of novel therapeutics46–48.
Methods
Reagents and antibodies. The following antibodies were used at the speciﬁed
concentrations for ﬂow cytometry analysis: mouse anti-human TRA-1–60-FITC
1:10 (560380, BD), mouse anti-human TRA-1–81-APC 1:10 (560793, BD), mouse
anti-human CD184 (CXCR4)-APC 1:10 (555976, BD), mouse anti-human
CD15-PE and CD15-FITC (561715 and 555401, BD), mouse anti-human CD24-PE
1:10 (560991, BD), mouse anti-human SSEA4-AlexaFluor647 1:10 (560219, BD),
mouse anti-human CD44-PE 1:10 (550989, BD), mouse anti-human CD133/2
(293C3)-PE 1:10 (130-090-853, Miltenyi), mouse APC isotype control 1:10
(555751, BD), mouse FITC isotype control 1:10 (555748, BD), mouse PE isotype
control 1:10 (555749, BD).
The following antibodies were used at the speciﬁed concentrations for
immunostainings: sex-determining region Y-box 2 (SOX2; AB5603, 1:500;
Chemicon); Oct-3/4 (sc-5279, 1:500; Santa Cruz Biotechnology); NANOG (EB06860,
1:500; Everest Biotech); NANOG (21624, 1:400, abcam); anti-phospho-Akt Ser473
(#9271, 1:50; Cell Signaling); anti-phospho-ERK1/2 Thr202/Tyr204 (#9101, 1:50;
Cell Signaling); neuron-speciﬁc class III b-tubulin (#MRB-435p and MMS-435p,
TUJ-1; 1:500; Covance); microtubule-associated protein 2 (#AB5622, MAP2; 1:500;
Millipore); PAX6 (PRB-278P; 1:1000; Covance), glial ﬁbrillary acidic protein
(#Z0334, GFAP; 1:500; Dako); a1-fetoprotein (A0008, AFP; 1:400; Dako); calponin
(M3556, 1:500; Dako); Ki67 (ab16667; 1:500; abcam); NESTIN (MAB5326, 1:500;
Millipore); human nuclear antigen (#MAB1281, HUNU; 1:250, Millipore); O4
(MAB345, 1:200; Milipore), PECAM-1 (#sc-1506, CD31; 1:50; Santa Cruz
Biotechnology); 4,6-diamidino-2-phenylindole (DAPI) (5mgml 1) 1:2,000 (D1306,
Invitrogen, Carlsbad, CA); and Alexa Fluor 488 goat anti-mouse (1:1,000,
Invitrogen), Alexa Fluor 488 donkey anti-goat (1:1,000, Invitrogen), Alexa Fluor 488
donkey anti-rabbit (1:1,000, Invitrogen) Alexa Fluor 568 donkey anti-mouse
(1:1,000, Invitrogen), Alexa Fluor 568 donkey anti-rabbit (1:1000, Invitrogen) and
Alexa Fluor 647 chicken anti-rabbit (1:1,000, Invitrogen).
The following chemicals were used at the speciﬁed concentrations: TGFb
inhibitor SB431542 10mM (Reagents Direct; #21-A94); PI3K inhibitor LY294002
10 mM (Sigma-Aldrich, St Louise, MO; #L9908); PD032591 MAPK inhibitor 1 mM
(Axon medichem; #Axon140); CHIR99021 3 mM (Axon Medichem; #Axon1386);
MMP-9 Inhibitor I 10 nM (Santa Cruz Biotechnology; #sc-311–437); FCCP 0.5 mM,
RotenoneþAntimycin A 1 mM and 0.1 mM (Rot/AA) and 2-Deoxy-D-glucose
5mM (2-DG) (Sigma). DMSO was used as a solvent and as a vehicle control in the
respective experiments.
Cell culture. Neonatal human ﬁbroblasts (HFF-1; ATCC), 293T and the human
glioma lines U-87 MG and LN229 (ATCC) were cultured in DMEM containing
10% FBS, 2mM GlutaMAX (Invitrogen), 50Uml 1 penicillin and 50mgml 1
streptomycin (Invitrogen). Human foreskin ﬁbroblasts (HFF) were grown in
collagen I coated plates (BD biosciences). Human iPSCs were cultured in
chemically deﬁned hES/hiPSCs growth media, mTeSR on growth factor reduced
matrigel (BD biosciences) coated plates. Brieﬂy, 70–80% conﬂuent iPSCs cells were
treated with dispase (Invitrogen) for 7min at 37 C and the colonies were dispersed
to small clusters and lifted carefully using a 5-ml glass pipette at a ratio of B1:4.
GTICs, previously reported and characterized5, were obtained from BioRep S.r.l.
(NS27Z þB AB0789) and maintained in culture as described elsewhere5. All cell
lines were maintained in an incubator (37 C, 5% CO2) with media changes every
day (iPSCs) or every second day (ﬁbroblasts, 293T cells, GTICs).
Plasmids. pMX-OCT4, pMX-SOX2, pMX-KLF4 and pMX-cMYC, were
obtained from Addgene (plasmids 17217, 17218, 17219 and 17220, respectively).
The shRNA p53 construct was previously described and validated49. Constructs
for the expression of mutant oncogenes were obtained from Addgene (RasV12
Neo (w108-1) #22259; EGFR D770-N771 insNPG #11016; EGFR (del3)
Figure 4 | Anti-cancer compound screening identiﬁes chemicals speciﬁcally targeting transformed iNPCs and primary GTICs. (a) Annexin V staining,
as measured by ﬂow cytometry, validates the role of lead compounds at the indicated concentrations and demonstrates a speciﬁc effect against primary
GTICs and transformed iNPCs for three of the compounds analysed (Nelarabine, Letrozole and Capecitabine). In contrast, Cabazitaxel demonstrated
group-dependent effects and targeting of WTiNPCs. Data are presented as a ratio to the values obtained in the respective DMSO control groups. Negative
values indicate increase viability in where basal Annexin V staining was higher in DMSO samples as compared with those treated with speciﬁc compounds;
(n¼ 3 group/condition with three technical replicates). (b,c) Treatment of transformed iNPCs and primary GTICs with the identiﬁed compounds and
metabolic modulators compromises glioma stem cell properties including migration (b, n¼ 3 group/condition with three technical replicates) and self-
renewal potential in single-cell assays (c; n¼ 3 group/condition with 24 technical replicates). (d) Tumour size measured on brain organotypic cultures for
each indicated condition. Data are independently plotted for each organotypic brain slice analysed (n¼43 condition with technical triplicates). (e)
Representative pictures of organotypic brain slices injected with primary GTICs and treated with each of the indicated compound. Brain slices were
immunostained with the indicated markers as follows: DAPI (blue), GFP (green) and Ki67 (red). Data are represented as mean±s.d. P values were
calculated by Student’s t-test or Mann–Whitney test when appropriate. *Po0.05. Scale bars, 100 mm (e).
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#11015; src Y527F #13660). Coding sequence for the mutant oncogenes
were removed by restriction enzymes and subcloned into a lentiviral backbone
with the In-Fusion system according to manufacturer’s instructions
(Takara/Clontech).
Retroviral and lentiviral production. Moloney-based retroviral vectors (pMXs)
were co-transfected with packaging plasmids (pCMV-gag-pol-PA and pCMV-
VSVg) in 293T cells using Lipofectamine 2000 (Invitrogen) according to
manufacturer’s instructions. Retroviral supernatants were collected 48 h after
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transfection, passed through a 0.45 mM ﬁlter to remove cellular debris and stored at
4 C for up to 7 days. Lentiviral vectors were co-transfected with packaging
plasmids (pMDL, Rev and VSVg) in 293T cells using Lipofectamine 2000
(Invitrogen) according to manufacturer’s instructions. Lentiviral supernatants were
collected 48 h after transfection, concentrated by ultracentrifugation at 19400 r.p.m.
for 2 h, resuspended in PBS and stored at  80 C.
Induced pluripotent stem cell generation and subculture. For the generation of
human iPS cells, primary HFF were infected with an equal ratio of retroviruses
(Oct4, SOX2, KLF4 and c-MYC) by spinfection of the cells at 1850 r.p.m. for 1 h at
room temperature in the presence of polybrene (4 mgml 1). After two serial
infections, cells were passaged onto fresh mouse embryonic ﬁbroblasts and
switched to hES medium containing DMEM/F12 (Invitrogen) supplemented with
20% Knockout Serum Replacement (Invitrogen), 1mM L-glutamine, 0.1mM
non-essential amino acids, 55M -mercaptoethanol and 10 ngml 1 bFGF
(preprotech). For the derivation of hiPS cells lines, iPS-like colonies were manually
picked and maintained on fresh mouse embryonic ﬁbroblast feeder layers for ﬁve
passages before being transferred onto Matrigel/mTesR1 conditions (n¼ 2 WTiPSC
clones). iPSCs with a knockdown of p53 were generated as described49. Brieﬂy,
HFF were infected with lentiviral particles expressing a shRNA against p53 before
iPSC reprogramming (n¼ 3 p53KDiPSC clones).
Embryoid body differentiation. Embryoid bodies (EBs) were produced from
adherent colonies that were enzymatically detached using dispase (0.5mgml 1)
for 15–45min, collected and then maintained in suspension using ultra low
attachment plates (corning) in the presence of EB medium containing DMEM/F12
supplemented with 15% fetal bovine serum, 2mM L-glutamine, 0.1mM non-
essential amino acids, and 1% penicillin/streptomycin. After 3–4 days, EBs were
transferred to 0.1% gelatin-coated polystyrene chamber slides and cultured in
differentiation medium (DMEM supplemented with 20% fetal bovine serum, 2mM
L-glutamine, 0.1mM 2-mercaptoethanol, 0.1mM non-essential amino acids and
1% penicillin/streptomycin) for 2–3 weeks to allow spontaneous endoderm
formation. The medium was changed every other day. For mesoderm
differentiation, EBs were maintained on gelatin-coated plate in differentiation
medium supplemented with 100mM ascorbic acid (Sigma). For ectoderm
differentiation, EBs were cultured on Matrigel-coated plates in 1% N2 and 0.5%
B27 (Invitrogen) medium supplemented with 1 mM retinoic acid for 2–3 weeks.
Derivation of iNPCs from iPSCs. Neural progenitor cell (NPC) induction was
based on a previous report with slight modiﬁcations50. The day before the start of
induction, hiPSCs (WTiPSCs and p53KDiPSCs) were passaged onto matrigel-coated
plates at about 20% conﬂuence and maintained in mTesR overnight. At day 0,
culture medium was then switched to Neural Induction Medium 1 (NIM-1: 50%
Advanced DMEM/F12 (Invitrogen), 50% Neurobasal (Invitrogen), 1 N2
(Invitrogen), 1 B27 (Invitrogen), 2mM GlutaMAX (Invitrogen) and 10 ngml 1
hLIF (Millipore), 4 mM CHIR99021 (Cellagentech, premade in 10mM DMSO
solution), 3 mM SB431542 (Cellagentech, premade in 10mM DMSO solution),
2 mM Dorsomorphin (Sigma) and 0.1 mM Compound E (EMD Chemicals Inc.).
Cells were treated with NIM-1 for 2 days, and then switched to Neural Induction
Medium 2 (NIM-2: 50% Advanced DMEM/F12, 50% Neurobasal, 1 N2, 1
B27, 2mM GlutaMAX, 10 ngml 1 hLIF, 4 mM CHIR99021, 3 mM SB431542 and
0.1 mM Compound E) for another 5 days. The cultures were then split onto
Matrigel-coated plates with Accumax (Innovative Cell Technologies) and cultured
in Neural Stem cell Maintenance Medium (NSMM) containing 50% Advanced
DMEM/F12, 50% Neurobasal, 1 N2, 1 B27, 2mM GlutaMAX, 10 ngml 1
hLIF, 3 mM CHIR99021 and 2 mM SB431542.
iNPC culture and multilineage neural differentiation. iNPCs were maintained
on Matrigel in NSMM and passaged once 80–100% conﬂuent using Accumax.
Medium was changed every day. For the initial six passages, iNPCs were treated
with 10 mM Y-27632 (Biomol Inc.) during splitting. For neuronal differentiation,
B1 105 human iNPCs cells were plated onto poly-ornithine (Sigma) and laminin
coated 35-mm dishes in NSMM medium. After 2 days, medium was switched
to Neurobasal media (Invitrogen) supplemented with N2 (Invitrogen), B27
(Invitrogen) and FGF2 (10 ngml 1; Peprotech). Four days later, FGF2 was
withdrawn from the medium, and after another 4 days, medium was switched to
Neurobasal media supplemented with B27 and brain derived neurotrophic factor
(BDNF, 20 ngml 1, R&D Systems). Differentiated cells were maintained up to 4
weeks after FGF2 withdrawal. For astrocyte generation, cells were treated with 5%
serum for 2–3 weeks.
iNPC transformation. Three days before lentiviral transduction, iPSC-derived
NPCs (WTiNPCs and P53KDiNPCs, passages 6–8) were passaged. On the day of
transduction, each of the four lentiviral preparations (RasV12, EGFR D770-N771;
EGFR (del3) and src Y527F) was thawed on a bed of ice, mixed at a 1:1:1:1
ratio (MOI of 0.75 per virus) in NSMM medium in the presence of polybrene
(4mgml 1). NPCs culture medium was replaced with the lentiviruses containing
medium and cells were incubated overnight at 37 C. The next day, the medium
was replaced with fresh NSMM. Transduced iNPCs (Ras/EGFR/SrciNPCs, P53KD-Ras/
EGFR/SrciNPCs were passaged for at least two more passages for stabilization before
performing analyses.
Flow cytometry analysis. For ﬂow cytometry analysis, cells were harvested using
TrypLE (Invitrogen), washed once with PBS and further incubated with the cor-
responding antibodies in the presence of FACS blocking buffer (1 PBS/10%FCS)
for 1 h on ice in the absence of light. After incubation, cells were washed thrice with
1ml of FACS blocking buffer and resuspended in a total volume of 200 ml
before analysis using an LSRII instrument (Becton-Dickinson, Fullertone, CA).
A minimum of 10,000 cells in the living population was analysed. Percentages are
presented after subtracting isotype background and referring to the total living
population analysed. Results are representative of at least two independent
experiments with a minimum of two technical replicates per experiment (nZ4)
and per condition.
For cell death assays, iNPCs and primary GTICs were treated with 5, 10 and
20 mM for the indicated chemotherapeutic compounds in duplicates in six-well-
plates. Human glioma lines (U-87 MG and LN229) were treated with 1mM for the
indicated compounds. 24 h after treatment, cells were dissociated by Accutase
(Innovative Cell Technologies, cat. no. AT-104) and Annexin V/PI staining
conducted following the manufacturer’s recommendations (88-8007-72 Annexin V
APC Ebiosciences). PI staining served to exclude dead cells and only Annexin V
cells present in the PI negative living cell population (indicative of early apoptosis)
were considered for analysis. All stainings were done in biological triplicate with
technical triplicates (n¼ 9 total) per line and per condition.
Cell sorting. Transformed iNPCs were sorted for CD15, CD133 and CXCR4 cells
using anti-CD15 (130-046-601; Miltenyi biotec), anti-CD133 (130-097-049;
Miltenyi biotec) and anti-CXCR4 (130-100-070; Miltenyi biotec) conjugated
magnetic beads according to the manufacturer’s instructions with slight
modiﬁcations. Brieﬂy, up to 109 cells were incubated with constant mixing at 4 C
with 100 ml of the corresponding magnetic beads in the presence of 100 ml of
Fc-blocking solution in a total volume of 500 ml FACS blocking buffer. After 1 h,
cells were sorted by two consecutive rounds of column separation in order to
increase purity by applying MACS separation magnets. Shortly, cells were
passed through the ﬁrst MS separation column allowing binding of labelled cells.
Non-labelled cells were washed thoroughly with 3ml ﬂuorescence-activated cell
sorting blocking buffer before elution of the labelled fraction. Eluted labelled cells
were then subjected to a second puriﬁcation step as described above. Both positive
and negative fractions were collected for further analyses.
Boyden chamber migration assays. Cells were treated with 10 mgml 1
Mitomycin C (Sigma) for 1 h before the assay. Cells were rinsed once with 1 PBS
(Invitrogen), and treated with TrypLE (Invitrogen) for 5min at 37 C. TrypLE was
neutralized with DMEM/F12 (Invitrogen)þ 10% FBS (HyClone). Cells were
centrifuged at 1000 r.p.m. for 5min, and resuspended in their respective basal
media. A total of 20,000 cells was seeded onto the upper chamber of each transwell
(BD). 1ml culture media was applied to the lower chamber of each transwell.
Migration assay was performed for 24 h in an incubator set at 37 C in the presence
or absence of MMP-9 Inhibitor I (10 nM), the metabolic modulators 2-DG (5mM),
FCCP (0.5 mM), Rot/AA (0.1 mM) and the chemotherapeutic compounds Nelar-
abine (10 mM), letrozole (10mM) and capecitabine (10mM). The cells attached onto
the upper side of the transwell ﬁlter were removed by a cotton stick. The migrated
cells attached onto the bottom side of the transwell ﬁlter were ﬁxed with 4% PFA
(Sigma), and visualized with 0.5% crystal violet staining (Sigma). Five different
areas of each chamber were randomly selected for photography with  5 objective
(Olympus). The average cell number/area was calculated for each chamber.
Biological Triplicates with technical triplicates (n¼ 9) were performed for each
cell line.
In vitro self-renewal and single-cell assays. Transformation assays were
conducted by modifying standard soft-agar protocols for the culturing of
iNPCs similar to what was previously described51. Brieﬂy, 2 104 cells were
individualized, embedded into 2% matrigel and seeded in 60-mm dishes. Biological
triplicates with technical triplicates (n¼ 6) were performed for each tested cell line
and condition.
For single-cell self-renewal assays the experimental setup was modiﬁed as
follows: undifferentiated (sorted or unsorted) iNPCs were dissociated and plated
into matrigel-coated 96-well plates as single cells as described52. Each condition
was done in 24 technical replicates with a minimum of three biological duplicates
(nZ62). One day after plating, all wells were treated with the respective
compounds as indicated. After 21 days, the colony number was evaluated by
microscopy analysis using an upright microscope (Olympus). For single-cell self-
renewal assays in the presence of PI3K (LY294002; 5 mM) and MAPK (PD98059;
5 mM) inhibitors, individual cells were plated as described above and the media
supplemented with the respective chemicals or the solvent control (DMSO) at the
indicated concentration and colonies counted after 21 days. Biological triplicates
with technical triplicates (n¼ 9) were performed for each tested cell line and
condition.
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Single-cell kill assays were conducted by plating individual iNPCs onto 96-well
plates as single cells before differentiation. Differentiation into neuronal lineages
was performed as described above in the presence of the indicated chemicals or the
respective DMSO controls. Cell survival was estimated with trypan blue after
differentiation over 28 days. Each condition was done in 24 replicates with a
minimum of two independent times (nZ48).
Immunoblotting. Cells were solubilized in lysis buffer (50mM Tris-HCl (pH 7.4),
10% Glycerol, 1% (v/v) Triton X-100, 100mM NaCl, 0.5mM MgCl2, 1mM
Na3VO4, 10mgml 1 aprotinin, 1mM PMSF, 1mM pepstatin and leupeptin), and
the resulting lysates were prepared by centrifugation at 16,000g for 15min at 4 C.
The protein concentration of cell lysates was tested using the protein assay
reagent (Bio-Rad) before immunoblotting. Protein samples were separated on
SDS–polyacrylamide gel electrophoresis, and transferred onto PVDF membrane
ﬁlters (PALL). The following primary antibodies were used according to the
manufacturer’s instructions: anti-phospho-Akt Ser473 (#9271, Cell Signaling),
anti-Akt (#9272, Cell Signaling), anti-phospho-ERK1/2 Thr202/Tyr204
(#9101, Cell Signaling), anti-ERK1/2 (#9102, Cell Signaling), anti-NANOG
(#ab21624, Abcam), anti-a-Tubulin (#T5168, Sigma) and anti-b-Actin (#sc-47778,
Santa Cruz). Uncropped images of the most important immunoblots are provided
in Supplementary Fig. 11.
RNA isolation and real-time PCR analysis. Total cellular RNA was isolated using
Trizol Reagent (Invitrogen) according to the manufacturer’s recommendations. An
amount of 1 mg of DNAse1 (Invitrogen) -treated total RNA was used for cDNA
synthesis using the iScript cDNA synthesis kit for PCR with reverse transcription
(BioRad). Real-time PCR was performed using the SYBR Green Supermix
(BioRad). The levels of expression of respective genes were normalized to corre-
sponding GAPDH values and are shown as fold change relative to the value of the
control sample. All samples were done in biological triplicate with a minimum of
two technical replicates (nZ5). The list of the primers used for real-time PCR
experiments are listed in the Supplementary Table 5.
Metabolic ﬂux analysis. Analysis of oxygen consumption rate (OCR) and
extracellular acidiﬁcation rate (ECAR) was performed using a Seahorse
extracellular ﬂux XF96 analyser (Seahorse Bioscience, Billerica, MA) in accordance
with manufacturer’s instructions. Brieﬂy, cells were seeded at a density of 1.5 104
cells per well in Matrigel-treated extracellular ﬂux 96-well culture microplates in
150ml of corresponding cell culture media and incubated overnight at 37 C. The
next day, before analysis, culture media was replaced with 150 ml of unbuffered
assay media and cells were incubated for 1 h at 37 C for pH and temperature
stabilization. Analysis of OCR and ECAR was performed simultaneously both at
basal conditions and after injections of the inhibitors in the XF Cell Mito Stress
Test Kit (1mgml 1 Oligomycin, 0.5 mM FCCP, 1 mM Antimycin Aþ 1 mM
Rotenone (Sigma)). To evaluate the effect of the respective PI3K and MAPK
inhibitors LY294002 and PD0325901 on cellular metabolism, cells were incubated
overnight (12 h) in the presence of 10 mM LY294002 or 1 mM PD0325901. The next
day, before analysis, culture media was replaced and analysis of OCR and ECAR
was performed as described above. Each condition was done in four technical
replicates with a minimum of four biological replicates (nZ16).
MTS assays. Analysis of cellular viability in the presence of respiratory
inhibitors was performed using MTS assay (Promega, G3580) according to the
manufacturer’s instructions. Brieﬂy, cells were seeded at a density of 2 104 cells
per well in Matrigel-treated 96-well culture microplates in 100 ml of culture media
and incubated for 4 h at 37 C. Next, the mitochondrial respiratory inhibitors
FCCP or 0.5 mM Antimycin Aþ 0.5 mM Rotenone (Sigma) were added at the
indicated concentrations. After 24 h of compound/DMSO treatment, 20 ml of MTS
reagent was applied to each well of 96-well plate. Absorbance at 490 nm was
recorded after 2 h incubation. Sextuplets were prepared for each condition.
ROS measurements. Mitochondrial-associated ROS levels and total intracellular
ROS levels were measured by staining cells with MitoSOX and H2DCFDA.
For mitochondrial superoxide, cells were washed with PBS solution, trypsinized
and resuspended in PBS in the presence of 5 mM MitoSOX (Invitrogen) for 15min
at 37 C. Subsequently, cells were washed twice with PBS solution containing 10%
FBS and analysed by FACS using an LSRII instrument (Becton-Dickinson). For
total intracellular ROS, cells were washed with PBS solution and incubated in HBSS
solution in the presence of 5 mM H2DCFDA (Invitrogen) for 30min at 37 C.
Afterwards, the HBSS solution was replaced with regular media and cells were
incubated for an additional 1 h at 37 C. Lastly, cells were washed with PBS
solution, trypsinized and resuspended in PBS solution containing 10% FBS for
FACS analysis using an LSRII instrument (Becton-Dickinson). As a positive
control, cells were incubated in the presence of the mitochondrial inhibitor
Antimycin A (Sigma) at a concentration of 0.1 mM for 30min at 37 C to induce
ROS production. Each condition was done in two technical replicates with three
biological replicates (n¼ 6).
Mitochondrial staining. For mitochondrial staining, cells were seeded on
Matrigel-treated cover slips at the appropriate densities. The next day, cells were
incubated for 30min at 37 C in regular media in the presence of 200 nM
MitoTracker Red (Invitrogen) for staining of mitochondria and 1 mgml 1
DAPI (Invitrogen) to stain the cell nuclei. Thereafter, cells were ﬁxed in 4%
paraformaldehyde and visualized by a confocal microscopy (Zeiss, Oberkochen,
Germany) with excitation at 578 nm and emission at 598 nm for MitoTracker Red,
and excitation at 359 nm and emission at 461 nm for DAPI detection. Each con-
dition was done in two technical replicates with three biological replicates (n¼ 6).
Gas chromatography/mass spectrometry/stable isotope labelling. For
GC–MS proﬁling analysis of intracellular metabolites, cells were seeded and
cultured in 6-well dishes (to about 1 million cells / 0.5mg cell protein per well).
Cells were washed quickly three times with cold PBS, and 0.45ml cold methanol
(50% v/v in water with 20mM L-norvaline as internal standard) was added to each
well. Culture plates were transferred to dry ice for 30min. After thawing on ice, the
methanol extract was transferred to a microcentrifuge tube. Chloroform (0.225ml)
was then added, the tube was vortexed and centrifuged at 10,000g for 5min at 4 C.
The upper layer was transferred to another microcentrifuge tube, dried in a
centrifugal evaporator and derivatized with 30 ml O-isobutylhydroxylamine
hydrochloride (20mgml 1 in pyridine, TCI) for 20min at 80 C, followed by 30ml
N-tert-butyldimethylsilyl-N-methyltriﬂuoroacetamide (Sigma) for 60min at 80 C.
After cooling overnight at 4 C, the mixture was then transferred to SHIMADZU
GCMS-QP2010 Plus for analysis.
GC–MS protocols and analysis were similar to those described before53, except
a modiﬁed temperature gradient was used for GC: Initial temperature was 130 C,
held for 4min, rising at 6 Cmin 1 to 243 C, rising at 60 Cmin 1 to 280 C,
held for 2min. Data were processed as before with quantiﬁcation against varied
amounts of standard mixtures run in parallel performed using MetaQuant.
Quantities were corrected for recovery using the L-norvaline internal standard.
For labelling experiments, cells were seeded as described above. Then cells
were changed to NSMM, with 50% 13C-glucose for labelling. The glucose was
isotopically labelled at all six carbon positions ([U- 13C6] glucose). After 24 h of
incubation, labelled cells were rinsed with cold PBS. Cells were then processed for
GC/MS sample extraction and derivatization, and analysed as described before53,54.
For normalization, protein quantiﬁcation was determined. Cells from separate
and replicate wells for GC/MS were rinsed once with ice-cold PBS and lysed in
ice-cold lysis buffer (25mM Tris (pH 8.0), 100mM NaCl, 1% TritonX-100 and
10% Glycerol) and one tablet of EDTA-free protease inhibitors (Roche; per 25ml).
The soluble fractions of cell lysates were isolated by centrifugation at 13,000 r.p.m.
for 15min. Protein concentration was determined by the Bradford method with
Bio-Rad DC Protein Assay Kit (Hercules, CA, USA).
Animals. Murine experiments presented hereafter were conducted with approval
of The Salk Institute Institutional Animal Care and Use Committee (IACUC),
under the protocol#08–025. NOD.Cg-PrkdcscidIl2rgtm1Wjl /SzJ mice (or NOD-
Scid IL2rgnull abbreviated as NSG; age, 7 weeks; males and females; weight, 20 g)
were purchased from the Jackson Laboratory, housed in air-ﬂow racks on a
restricted access area and maintained on a 12-h light/dark cycle at a constant
temperature (22±1 C). For all experiments involving the use of animals, no
inclusion/exclusion criteria were applied in the present study.
Teratoma assay. Severe combined immune NSG male mice (n¼ 2 animal/iPS
clone; 5 clones total), B8 weeks old, were injected with iPSCs (1 million for each
injection site, approximately) subcutaneously in the testicular parenchyma.
Additionally, undifferentiated iPSCs were stereotactically injected into the brain of
immunocompromised NSG mice (n¼ 2 animal/iPS clone; ﬁve clones total).
Mice were sacriﬁced 8 weeks after the injections or when a tumour was detected
by palpation or when animals displayed signs of distress, whichever came ﬁrst.
Teratoma formation was assessed by immunoﬂuorescence techniques.
Randomization was unnecessary and no blinding was done.
In vivo tumour formation. For cell preparation, cells were rinsed once with 1XPBS
(Invitrogen), and treated with TrypLE (Invitrogen) for 5min at 37 C. TrypLE was
neutralized with DMEM/F12 (Invitrogen)þ 10% FBS. Cells were centrifuged at
1000 r.p.m. for 5min, and resuspended in PBS (2 105ml 1 or 500ml 1 for
5 105 and 500 transplanted cells, respectively). Cells were kept on a bed of ice
before transplantation. For cell transplantation, anaesthetized NSG mice were
inserted in a stereotactic frame, the skull surface was exposed and a hole was drilled
at the appropriate site to allow single/unilateral (right hemisphere) injection of the
cell preparations. Antero-posterior (AP), lateral (L) and vertical (V) coordinates
(in mm) for cell transplantations were taken relative to the bregma: APþ 0.5,
Lþ 2, V  1.5. For cell injections, a 10 ml Hamilton syringe was used and the ﬂow
rate set atB0.5 ml min 1 (2.5ml or 0.5 ml animal for 5 105 and 500 transplanted
cells, respectively). For each condition, ﬁve animals were injected. Randomization
was unnecessary and no blinding was done.
For secondary transplantation experiments, primary recipient animals were
sacriﬁced by carbon dioxide (CO2) overdose and their brains immediately
removed. The tumour was then extracted under stereomicroscope with surgical
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tools, in sterile conditions. The tumour mass was cut into small pieces and
placed in TrypLE solution for 15min at 37 C. The tumour was fully dissociated
by mechanical dissociation to obtain a single-cell solution, and passed
through a 0.45 mm ﬁlter. Then, the cells were prepared and injected into
immunocompromised mice as described above. Of note, tumour extraction, cell
preparation and cell injection were performed the same day. For each condition,
ﬁve animals were injected. Randomization was unnecessary and no blinding was
done.
Animal perfusion/tissue sectioning. Animals were daily monitored and
sacriﬁced/perfused when showing cues of sickness (that is, dehydrated, lethargic,
scruffy and/or hunched). For perfusion, mice were sacriﬁced by carbon dioxide
(CO2) overdose and then transcardially injected with 20ml ice-cold saline (0.90/00
NaCl), followed by 50ml ice-cold 4% paraformaldehyde (PFA, pH 7.4; 4 C).
Brains were then extracted and post-ﬁxed in PFA overnight at 4 C. Thirty-six to
forty hours before sectioning, brains were cryoprotected in a 30% sucrose solution.
Frozen coronal sections (35mm thickness) were cut with a cryostat (Leica)
and were either collected onto positively charged slides or kept at  20 C
into an ethylenglycol-based cryoprotectant solution until being processed for
immunostainings. Before performing cryosections, whole brain pictures were
taken with a camera.
Haematoxylin/eosin staining. Tissue sections on positively charged slides were
processed for haematoxylin-eosin staining by dipping the slides in a series of baths
as follow: distilled water (30 s), haematoxylin (5min); distilled water (1min); 0.5%
eosin Y (2min); 95% Ethanol (30 s 2); 100% ethanol (30 s 2); and xylene
(30 s 2). Depex mounting medium and glass cover slips were used to mount the
slides. Slides were analysed by using an upright microscope (Olympus).
Immunoﬂuorescence analyses. Brieﬂy, cells were washed thrice with PBS and
ﬁxed using 4% PFA in 1 PBS for 12min and then washed three times in PBS. For
tissue analysis, ﬁxed ﬂoating sections maintained in a cryoprotectant solution were
washed in PBS before being immunostained. Fixed cells/tissues were blocked and
permeabilized for 1 h at RT with 3% BSA/5% appropriate serum/1 PBS in the
presence of 0.1% Triton X-100 and 0.3M glycine. Subsequently, cells/tissue
sections were incubated with the indicated primary antibody either for 1 h at room
temperature or overnight at 4 C. Cells/tissue sections were then washed thrice with
1 PBS and incubated for 1 h at RT with the respective secondary antibodies and
20min with DAPI. Cells/tissue sections were washed thrice with 1 PBS before
analysis. Cells/tissue sections were analysed by confocal microscopy. Confocal
image acquisition was performed using a Zeiss LSM 780 or LSM 710 laser scanning
microscope (Carl Zeiss).
Gene expression analysis. For gene expression analyses, RNA was puriﬁed using
the RNeasy Plus mini kit (74134, Qiagen). Purity and integrity of the RNA samples
were assessed by spectrophotometry and nanoelectrophoresis using the NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the
Nano lab-on-a-chip assay for total eukaryotic RNA using Bioanalyser 2100 (Agilent
Technologies, Palo Alto, CA), respectively. Only samples with high purity and high
integrity were subsequently used in microarray experiments.
Microarray expression proﬁles were obtained using the Affymetrix GeneChip
Human Gene 1.0 ST Array (Affymetrix, Santa Clara, CA). Ampliﬁcation, labelling
and hybridizations were performed according to protocols from Ambion (Ambion/
Applied Biosystems, Foster City, CA, USA) and Affymetrix (Affymetrix Inc.).
Brieﬂy, 200 ng of total RNA were ampliﬁed using the Ambion WT Expression Kit
(Ambion/Applied Biosystems), labelled using the WT Terminal Labeling Kit
(Affymetrix) and then hybridized to Human Gene 1.0 ST Array (Affymetrix) for
16 h at 45 C and 60 r.p.m. in a GeneChip Hybridization Oven 640. Following
hybridization, the array was washed and stained in the Affymetrix GeneChip
Fluidics Station 450. The stained array was scanned using an Affymetrix GeneChip
Scanner 3000 7G, generating CEL ﬁles for each array. Normalized and log
transformed gene expression values were ﬁltered using a variance ﬁlter (s/s max)
of 0.2. Each variable was standardized by subtraction of its mean value and division
by its standard deviation across all samples. One p53KD-Ras/EGFR/SrciNPC outlier
sample was removed from further analysis. Differential expression analysis was
carried out using ANOVA in Qlucore Omics Explorer 2.3. Probes with a q value
o0.01 were considered differentially expressed. The differentially expressed probes
were then clustered using hierarchical clustering and only the probes (n¼ 463) that
displayed high correlation between the GTICs and p53KD-Ras/EGFR/SrciNPC samples
were displayed in the heatmap. Pathways analysis was performed using IPA
software (Ingenuity Systems, build v. 308606M, content v. 18488943).
Chip-Seq and methylation analysis. ChiP-Seq data was mapped and loaded into
Seqmonk tools (Babraham Institute) and duplicate reads were removed. Peaks were
deﬁned as a contiguous set of reads that were enriched by at least 10-fold. A 50 base
pair gap was allowed to prevent large peaks from being broken into multiple small
peaks. The number of reads in each peak were counted, corrected for total read
count and log transformed. An intensity difference test was used to identify
differential SOX2-binding sites. An intensity difference test is a pairwise statistical
test using the general distribution of the data and tests whether a particular point is
likely to be an outlier when compared with the overall distribution of the data. The
test takes each point and tests a subset of points from the pair of samples being
examined and then constructs a distribution of the differences between the two
data sets. The distribution is then compared with a normal distribution allowing
for a P value to be calculated. A FDR of 0.05 was used as a cutoff. Genes within
100 kb of the differentially bound peak were considered to be associated with
SOX2-binding events.
For methylation analyses, DNA was puriﬁed by using DNeasy kit (69504,
Qiagen), quantiﬁed (Qubit dsDNA BR Assay, Life Technologies) and bisulﬁte-
converted (EZDNA Methylation Kit, Zymo Research) according to the
manufacturer’s protocol. Bisulﬁte-converted DNA was then labelled and
hybridized to the Inﬁnium Human Methylation 450K beadchip (Illumina) and
scanned on a HiScan (Illumina). Samples were normalized and ﬁltered using the
statistical programming language R (http://www.r-project.org/) (v.3.0.1) and the R
package minﬁ (v.1.6.0). Brieﬂy, samples were ﬁrst control-normalized using
Illumina’s internal bead controls and probes with a detection P value 40.01 in at
least one sample were discarded. The samples were then SWAN normalized using
the minﬁ package and b values (Methylated allele intensity/ Unmethylated allele
intensityþmethylated allele intensity) were exported. Probes with less than a max
b—min b of 0.5 were removed.
Compound screening. 101 anti-cancer compounds were provided by the National
Cancer Institute-chemotherapeutic agents repository. A full list is provided in
Supplementary Table 7. For MTS assays, 96-well plates were coated with matrigel
(BD, cat. no. 354230) in a 37 C cell culture incubator for 2 h. iNPCs and GTICs
were enzymatically dissociated by Accutase (Innovative Cell Technologies, cat. no.
AT-104). Live cell number was counted using a hemocytometer in the presence of
Trypan Blue (Gibco, cat. no. 15250). For each iNPC line, 30,000 live cells were
resuspended in 50ml NSMM and seeded into one well of 96-well plate. For
GTICs, 15,000 live cells were resuspended in 50 ml NSMM and seeded into one well
of 96-well plate. The cells were allowed to grow in a 37 C cell culture incubator for
24 h before compound/DMSO treatment. Compound/DMSO were diluted in
NSMM (ﬁnal concentration of 10 mM) and added into each well to make a 100-ml
ﬁnal volume. After 24 h compound/DMSO treatment, 20 ml MTS (Promega,
G3580) was applied to each well of 96-well plate. Absorbance at 490 nm was
recorded after 2 h incubation. Quadruplets were prepared for one compound/line.
For Flow Cytometry analysis, cells were treated in the presence of 5, 10 and 20 mM
in duplicates in six-well-plates. 24 h after treatment cells were dissociated by
Accutase (Innovative Cell Technologies, cat. no. AT-104) and Annexin V/PI
staining conducted following the manufacturer’s recommendations (88-8007-72
Annexin V APC Ebiosciences). PI staining served to exclude dead cells and only
Annexin V cells present in the PI negative living cell population (indicative of early
apoptosis) were considered for analysis. All stainings were done in biological and
technical triplicates per line and per condition.
Brain organ cultures. Brain organotypic slices were obtained from adult male
NSG mice as previously described55,56. Brieﬂy, 3–8, 300mm slices per murine brain
were obtained with a Leica VT1200 microtome and cultured over 0.4 mm air–liquid
interface membranes (Millipore) for 24 h. 200,000 cells were then injected and
tumour formation allowed for the next 72 h. Brain slices were then incubated in the
presence of the indicated chemicals or the respective DMSO control for 72 h before
immunoﬂuorescence analysis. Each condition was done in two technical replicates
with a minimum of three biological replicates (nZ6).
Statistical evaluation. Statistical analyses were performed by using SPSS/PCþ
statistics 11.0 software (SPSS Inc., Chicago, IL). All data presented a normal dis-
tribution. Statistical signiﬁcance was evaluated using standard unpaired Student’s t
test (two-tailed, 95% conﬁdence intervals, Po0.05) with Welch’s correction when
appropriate. For multiple comparison analysis, one-way ANOVA with Dunnett’s
or Bonferroni correction post-test was applied when appropriate (Po0.05).
Comparisons of groups with small sample size (no6) were performed as follows:
(i) Mann–Whitney test (two-sided, 95% conﬁdence level; Po0.05) was used; (ii)
Kruskal–Wallis test with Dunn’s post-test (Po0.05) has been applied for multiple
comparisons. All data are presented as mean±s.d. and represent a minimum of
two independent experiments with at least two technical replicates.
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